| Open Document File Size: 502,89 KBShare Result on Facebook
City Copenhagen / / Company Eli Lilly / Novartis / Eli Lilly and Company / Targeted Milestone / Seattle Genetics HuMax-TF / FINANCIAL REVIEW / Roche / Genmab A/S / GlaxoSmithKline / GSK Ofatumumab / Cormorant Pharmaceuticals / Janssen Biotech Daratumumab / Janssen Biotech Inc. / Kyowa Hakko Kirin / Seattle Genetics / River Vision Development Corporation / Janssen Biotech Genmab A/S / Glaxosmithkline plc / / Country Japan / United States / Denmark / / Currency GBP / USD / DKK / / Event Business Partnership / Earnings Announcement / FDA Phase / Conference Call / M&A / Earnings Guidance / / / IndustryTerm therapy of cancer / technology collaborations / biotechnology / pipeline products / potential regulatory applications / technology base / antibody technologies / treatment of cancer / treatment of certain chronic lymphocytic leukemia / manufacturing / tier pharmaceutical / generation technologies / / MedicalCondition III Relapsing-Remitting Multiple Sclerosis / macular edema / Multiple Myeloma / headache / leukopenia / chronic lymphocytic leukemia / IV1/III Follicular Lymphoma / bronchitis / potential cancer / refractory multiple myeloma / nausea / infectious / double refractory multiple myeloma / respiratory tract infections / fatigue / diarrhea / infections / respiratory tract infection / sepsis / autoimmune diseases / marketed cancer / abdominal pain / tumor / nervous system disease / pneumonia / III Diffuse Large B-cell Lymphoma / central nervous system diseases / cancer / burn / tumors / disease / arthralgia / neutropenia / certain chronic lymphocytic leukemia / autoimmune disease / infectious diseases / III Waldenstrom’s Macroglobulinemia / cough / eye disease / ofatumumab cancer / rash / herpes simplex / anemia / / MedicalTreatment chemo / chemotherapy / antibody therapy / / Organization FDA / European Union / / Person Jan van de Winkel / / / Position Chief Executive Officer / bulky refractory CLL ofatumumab vs physician / Governor / / Product dexamethasone / cyclophosphamide / Revlimid / Arzerra / Arzerra® (ofatumumab) / CD20 / US / United States / / Technology ADC / generation technologies / antibodies / biotechnology / antibody technologies / chemotherapy / / URL www.genmab.com/duobody / www.genmab.com/products / www.genmab.com/daratumumab / www.genmab.com / www.genmab.com/ofatumumab / http /
SocialTag |
Microsoft Word - 22 q1_report_2014_uk_070514